title: New measurement of hepatic blood flow by xenon CT system: an animal study with PGE1.
abstract: BACKGROUND
  A new Xenon computed tomography (CT) system was developed to measure both hepatic arterial and portal venous tissue blood flow (HATBF/PVTBF) non-invasively. Despite its clinical trial, the effect of prostaglandin E1 (PGE1) on hepatic hemodynamics is not well investigated. In a rabbit model, we evaluated the accuracy of this system by comparing it with the electromagnetic blood flowmeter (EMBF), the pharmacological effect of PGE1 on the fractional hepatic hemodynamics.
  
  
  METHODS
  Seven NZW-rabbits were used. Serial abdominal CT scan was obtained every min before and during the 4 min inhalation of the Xenon gas, followed by 5 min administration of oxygen air. From these images, HATBF and PVTBF were separately calculated with a special new imaging system. We also used EMBF during laparotomy, and directly measured the hepatic arterial and portal venous flow with or without PGE1 administration.
  
  
  RESULTS
  Xenon CT showed HATBF of 18.4 +/- 4.5 (ml/min/100 g) and PVTBF of 69.4 +/- 15.0, was almost identical with those of EMBF (19.8 +/- 5.7 and 67.2 +/- 19.1, respectively). After PGE1 administration, Xenon CT showed 22.9 +/- 4.6 and 76.5 +/- 20.5, while those with EMBF were 21.0 +/- 6.5 and 84.7 +/- 21.6, respectively. There were significant correlations (P < 0.01) in total HTBF, HATBF, and PVTBF between results of Xenon CT and EMBF.
  
  
  CONCLUSIONS
  Xenon CT with a newly developed imaging system enables us to measure the fractional hepatic tissue blood flow in rabbits, differentially and accurately. Venous administration of PGE1 increased total hepatic blood flow, mainly affecting the portal blood flow.
authors.affiliation: Department of Surgery and Clinical Oncology, Osaka University Graduate School of Medicine, Osaka, Japan. hayashis@image.ocn.ne.jp
authors.forename: Shouho
authors.initials: S
authors.lastname: Hayashi
authors.forename: Keizo
authors.initials: K
authors.lastname: Dono
authors.forename: Junzo
authors.initials: J
authors.lastname: Shimizu
authors.forename: Takamichi
authors.initials: T
authors.lastname: Murakami
authors.forename: Manabu
authors.initials: M
authors.lastname: Takamura
authors.forename: Tonsok
authors.initials: T
authors.lastname: Kim
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Hori
authors.forename: Zhenhui
authors.initials: Z
authors.lastname: Lu
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Nagano
authors.forename: Shoji
authors.initials: S
authors.lastname: Nakamori
authors.forename: Masato
authors.initials: M
authors.lastname: Sakon
authors.forename: Hironobu
authors.initials: H
authors.lastname: Nakamura
authors.forename: Morito
authors.initials: M
authors.lastname: Monden
mesh_terms: D000280:Administration, Inhalation; D000527:Alprostadil / Q000008:administration & dosage; D000818:Animals; D001783:Blood Flow Velocity; D006499:Hepatic Artery; D006503:Hepatic Veins; D008099:Liver / Q000098:blood supply*; D011169:Portal Vein; D011817:Rabbits; D014054:Tomography / Q000379:methods*; D014978:Xenon / Q000008:administration & dosage
chemical_list: D014978:Xenon; D000527:Alprostadil